Drug pipeline

Chondrosarcoma Market Outlook to 2032: Emerging Therapies and Market Access Drive Growth in the 7MM, Addressing Unmet Needs in Rare Bone Cancer Treatment - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 9, 2023
Health, Oncology, TKI, EU4, Ivosidenib, Disease, Radiation, Chondrosarcoma, USD, NCCN, Patient, IDH2, IDH1, United Kingdom, Dasatinib, Drug pipeline, Pharmaceutical industry, Epidemiology

It also includes insights from key opinion leaders, pipeline activities, and market access and reimbursement scenarios for chondrosarcoma therapies.

Key Points: 
  • It also includes insights from key opinion leaders, pipeline activities, and market access and reimbursement scenarios for chondrosarcoma therapies.
  • Chondrosarcoma Cases and Market Size: As per NCCN Guidelines, nearly 65% of chondrosarcoma cases are related to IDH1 or IDH2 mutations.
  • Limited Treatment Options: Conventional chondrosarcomas, the major subtype, are considered resistant to chemotherapy and radiation, resulting in limited treatment options.
  • Market Access and Reimbursement: Reimbursement of rare disease therapies like chondrosarcoma can be limited due to high costs and lack of specific approaches to evaluating rare disease drugs.

Informa Pharma Intelligence Launches 30th Edition Pharma R&D Annual Review

Retrieved on: 
Thursday, March 24, 2022
HCV, Degenerative disease, Plasma protein binding, D, Growth, Clinical trial, AAV, Nass, Drug pipeline, Novartis, Cancer, Lloyd, Intelligence, Rare, Roche, Pulse, Finger, Industry, Travel, Infection, Cell, COVID-19, Sofosbuvir, Sporting News Player of the Year Award, GLOBE, CD274, Company, NAS, PD-L1, Disease, Lilly, Gene, Fine chemical, Pharmaceutical industry, Medical device

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence , the global business intelligence provider for the biopharma industry, today announced the launch of its 30 th Edition Pharma R&D Annual Review .

Key Points: 
  • NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence , the global business intelligence provider for the biopharma industry, today announced the launch of its 30 th Edition Pharma R&D Annual Review .
  • Novartis has 64.8% of its pipeline targeting rare diseases, the highest of any top 10 pharma, with Lilly the lowest, at 28.2%.
  • [2004 Pharma R&D Report]
    Sovaldi (sofosbuvir), Gileads first-in-class small molecule for hepatitis-C, was in our list of novel NASs from 2013.
  • [2021 Pharma R&D Report]
    For more information, or to view the current and past reports, visit Informa Pharma Intelligence or contact [email protected] .

Global Lyme Disease Preventive Vaccine & Shot Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 22, 2021
Infectious Diseases, Pharmaceutical, Health, Tick, Porter's five forces analysis, Lyme disease, USD, Drug pipeline, Population, Vaccine, CAGR

The "Global Lyme disease Preventive Vaccine & Shot Market Size By Type, By geographic Scope And Forecast" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Lyme disease Preventive Vaccine & Shot Market Size By Type, By geographic Scope And Forecast" report has been added to ResearchAndMarkets.com's offering.
  • The Lyme disease Preventive Vaccine & Shot Market report provides a holistic evaluation of the market for the forecast period.
  • The Lyme disease preventive vaccine and shot market is expected to drive due to the undergoing development of the vaccines.
  • This report provides an all-inclusive environment of the analysis for the Lyme disease Preventive Vaccine & Shot Market.

Anal Cancer Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Pharmaceutical, Health, Oncology, Pipeline, Drug pipeline, Pipelines in Canada

The "Anal Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anal Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Anal Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Anal Cancer pipeline landscape.
  • This segment of the report provides insights about the different Anal Cancer drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Anal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Obesity Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 29, 2021
Health, Diabetes, Other Health, Fitness & Nutrition, General Health, Pharmaceutical, Pipeline, Drug pipeline, Obesity, Pipelines in Canada, Medical specialties, Clinical medicine

The "Obesity - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Obesity - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Obesity - Pipeline Insight, 2021" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Obesity pipeline landscape.
  • This segment of the report provides insights about the different Obesity drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Cachexia Pipeline Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 29, 2021
Health, Pharmaceutical, Medical specialties, Medicine, Clinical medicine, Cachexia, Geriatrics, Rehabilitation medicine, Pipeline, Drug pipeline

The "Cachexia - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cachexia - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Cachexia - Pipeline Insight, 2021" report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Cachexia pipeline landscape.
  • This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Thyroid Cancer Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Pharmaceutical, Health, Oncology, Anatomy, Thyroid disease, Branches of biology, Organs anatomy), Endocrine diseases, Endocrine system, Glands, Thyroid, Pipeline, Drug pipeline

The "Thyroid Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thyroid Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Thyroid cancer - Pipeline Insight, 2021" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Thyroid cancer pipeline landscape.
  • This segment of the report provides insights about the different Thyroid cancer drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Thyroid cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Kaposi's Sarcoma Pipeline Insight Market Report 2021 Featuring sEphB4-HAS (Vasgene Therapeutics) - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Health, Biotechnology, Kaposi, Pipeline, Drug pipeline

The "Kaposi's Sarcoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Kaposi's Sarcoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Kaposi's sarcoma - Pipeline Insight, 2021" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Kaposi's sarcoma pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Kaposi's sarcoma R&D.
  • Kaposi's sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

COVID-19 Pipeline Insight Report, Q2 2021 Edition - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 22, 2021
Infectious diseases, Pharmaceutical, Health, Pipeline, Drug pipeline, Oil pipelines, Pipelines in Canada, Keystone Pipeline

The "COVID-19 - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "COVID-19 - Pipeline Insight, 2021," report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in COVID-19 pipeline landscape.
  • It covers the pipeline drug profiles, including clinical and nonclinical stage products.
  • It further highlights the inactive pipeline products in this space.

Global Antisense Oligonucleotide Therapeutics Pipeline Insight 2021 Report - ResearchAndMarkets.com

Retrieved on: 
Monday, June 14, 2021
Health, Pharmaceutical, Branches of biology, Biology, DNA, Molecular biology, RNA, Sense, Virology, Life sciences, Drug pipeline

The "Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Antisense Oligonucleotide Therapeutics pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Antisense Oligonucleotide Therapeutics R&D.
  • Antisense Oligonucleotide Therapeutics pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.